Jeena Sikho Lifecare Limited has informed the Exchange regarding 'Research and Review Articles authored by experts associated with Jeena Sikho Lifecare Limited, including our Managing Director, medical consultants, and senior Ayurvedic professionals.'.
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jeena Sikho Lifecare has informed the stock exchange about 10 research and review articles published by its experts, including Managing Director Acharya Manish Ji (Manish Grover) and 14 medical consultants and Ayurvedic professionals. The articles cover Ayurvedic treatments for conditions such as male infertility (azoospermia), chronic kidney disease (CKD), rheumatoid arthritis, uterine fibroids, metastatic lung cancer, and psoriasis. They were published in journals like the International Journal of Ayurveda and Pharma Research and the European Journal of Biomedical and Pharmaceutical Sciences. One case study reported a patient with no sperm count improving to 28 million/ml after six months of Ayurvedic treatment. The disclosure is filed under SEBI's Regulation 30 listing requirements.
This is a routine regulatory disclosure about research output and does not directly affect the company's financials or stock price. However, it may boost brand credibility by showcasing clinical case studies and Ayurvedic treatment outcomes, which could support the company's positioning in the wellness and healthcare segment.